MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding another drug improve MDS treatment?
Disease control OngoingThis study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control TerminatedThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Two-Drug cocktail aims to beat back rare bone marrow cancers
Disease control OngoingThis study tests whether adding venetoclax to ASTX727 (a two-in-one pill) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will be randomly assigned to one of the two trea…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New Triple-Drug cocktail targets tough blood cancers
Disease control OngoingThis early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that can control the disease. Sixteen adults aged 18 and older a…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC